Quince Therapeutics Inc. (NASDAQ:QNCX) closed Wednesday at $0.73 per share, down from $0.73 a day earlier. While Quince Therapeutics Inc. has underperformed by -0.01%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, QNCX fell by -94.03%, with highs and lows ranging from $14.69 to $0.66, whereas the simple moving average fell by -74.32% in the last 200 days.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
Analysis of Quince Therapeutics Inc. (QNCX)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Quince Therapeutics Inc.’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -63.10% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 19.90, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and QNCX is recording an average volume of 223.65K. On a monthly basis, the volatility of the stock is set at 9.97%, whereas on a weekly basis, it is put at 9.90%, with a loss of -2.67% over the past seven days. Furthermore, long-term investors anticipate a median target price of $37.00, showing growth from the present price of $0.73, which can serve as yet another indication of whether QNCX is worth investing in or should be passed over.
How Do You Analyze Quince Therapeutics Inc. Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.50%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 25.50% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in QNCX shares?
The recent increase in stakes in QNCX appears to be a result of several institutional investors and hedge funds increasing their positions. EPIQ Capital Group LLC’s position in QNCX has decreased by -37.21% in the first quarter. The company now owns 2,056,669 shares of the stock, with a value of $2.06 million, following the sale of -1,218,879 additional shares during the last quarter. The Vanguard Group, Inc. made another increased to its shares in QNCX during the first quarter, upping its stake by 10.75%. During the last quarter, the company dropped down 84,018 additional shares for a total stake of worth $0.87 million, bringing number of shares owned by the company to 865,845.
During the first quarter, Federated MDTA LLC subtracted a -13,523 position in QNCX. BlackRock Fund Advisors purchased an additional 30092.0 shares in the last quarter, increasing its holdings by 6.43%, now holding 0.5 million shares worth $0.5 million. At the end of the first quarter, Two Sigma Investments LP decreased its QNCX holdings by -2.51% and now holds 0.5 million QNCX shares valued at $0.5 million with the lessened 12818.0 shares during the period. QNCX shares are owned by institutional investors to the tune of 25.50% at present.